Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.73)
# 2,009
Out of 4,911 analysts
108
Total ratings
37.86%
Success rate
7.63%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.81 | +3,546.41% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.68 | +1,673.31% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.49 | +1,037.88% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.86 | +491.40% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $44.97 | +11.19% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.73 | +882.66% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.46 | +4,703.49% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.35 | +4,453.19% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.84 | +1,566.67% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.89 | +2,218.34% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $3.08 | +1,296.10% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.67 | +169.87% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.28 | +485.94% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.57 | +320.17% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $9.76 | +115.16% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.33 | +777.60% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.73 | +5,409.64% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $4.87 | +926.69% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $7.99 | +1,326.78% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $3.65 | +5,379.45% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $14.50 | +127.59% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $19.59 | +104.19% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.62 | +2,183.95% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $5.05 | +533.66% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $14.94 | +415.39% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.56 | +12,367.72% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.26 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $15.74 | +217.66% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.17 | +538.30% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $11.36 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $3.83 | +578.85% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $147.61 | -81.03% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $6.53 | +12,916.85% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $12.21 | +71.99% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.81
Upside: +3,546.41%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.68
Upside: +1,673.31%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.49
Upside: +1,037.88%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.86
Upside: +491.40%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $44.97
Upside: +11.19%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.73
Upside: +882.66%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.46
Upside: +4,703.49%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.35
Upside: +4,453.19%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.84
Upside: +1,566.67%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.89
Upside: +2,218.34%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $3.08
Upside: +1,296.10%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.67
Upside: +169.87%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.28
Upside: +485.94%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.57
Upside: +320.17%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $9.76
Upside: +115.16%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.33
Upside: +777.60%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.73
Upside: +5,409.64%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $4.87
Upside: +926.69%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $7.99
Upside: +1,326.78%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $3.65
Upside: +5,379.45%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $14.50
Upside: +127.59%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $19.59
Upside: +104.19%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.62
Upside: +2,183.95%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $5.05
Upside: +533.66%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $14.94
Upside: +415.39%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.56
Upside: +12,367.72%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.26
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $15.74
Upside: +217.66%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.17
Upside: +538.30%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $11.36
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $3.83
Upside: +578.85%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $147.61
Upside: -81.03%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $6.53
Upside: +12,916.85%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $12.21
Upside: +71.99%